iiinova — where your digital self keeps evolving

Replies

Lara Green @laragreen.bsky.social · 28/03/2025

Unfortunate to see today’s news from Vertex about their VX-264 therapy for #T1D but this is why we always have ‘multiple shots on goal’! Considering that the same cells are being used as in VX-880 (so far great data) it’s reasonable to assume that the device encapsulation was the problem here.

150 5

Lara Green @laragreen.bsky.social · 28/03/2025

For those curious why the same cells are effective on one trial (VX-880) and not another (VX-264)… The 880 trial is putting the cells directly into the body and using immunosuppression drugs to protect them. The 264 trial was putting the same cells in a ‘teabag’ device that goes under the skin

120 2

Francis Lynn 🇨🇦 @nictitate.bsky.social · 28/03/2025

unfortunate but not terribly surprised by this outcome

040 4